VYNE and Yarrow publish investor presentation for proposed merger

VYNE Therapeutics Inc.

Yarrow Bioscience published an investor presentation on May 21, 2026, now available on VYNE's website.
VYNE previously filed Form S-4 (No. 333-294804) with proxy statement/prospectus for the proposed Yarrow acquisition.
Presentation provides overview of Yarrow's business as part of the pending merger with VYNE.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.